Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.
The mHUB MedTech Accelerator is a six-month program, based in Chicago, run in partnership with Baxter and Edward-Elmhurst Health Venture Capital. The application deadline is Monday, August 23.
Ipsen is shoring up its neuroscience pipeline via a deal that gives it the option to license drugs that Exicure is developing for Huntington’s disease and Angelman syndrome. The programs are based on Exicure’s proprietary technology that produces nucleic acid therapies capable of delivery deep into the brain.
The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.
7wireVentures, the venture capital firm that backed Livongo and other healthcare technology companies, raised $150 million for a new connected consumer fund. It’s already made two investments in patient navigation startups.
VillageMD, a primary care startup that has Walgreens as a big backer, is reportedly planning to go public. The company has plans to open hundreds of co-located primary care clinics at Walgreens pharmacies.
A top executive at Chicago-based Loretto Hospital has resigned after controversy surrounding vaccination events held at businesses with close ties to him. Mayor Lori Lightfoot said an independent investigation needs to be conducted.
In a wide-ranging interview, Maggie Huston, associate general counsel for precision medicine company Tempus, discusses how to balance innovation with safety as the FDA grapples with AI/ML and new, more complex technology, as well how her company quickly reacted to Covid-19.
Interactive, cloud-based video games are designed to tackle pharma’s current challenge: engaging doctors virtually during a pandemic. But the tools are likely to outlive the circumstances in which they were born.
As part of our conferences and to augment panel discussions and presentations, we are launching MedCity News: Spotlight to use video to tell the story of important companies, executives and healthcare initiatives.